Welcome to our dedicated page for CTYX news (Ticker: CTYX), a resource for investors and traders seeking the latest updates and insights on CTYX stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect CTYX's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of CTYX's position in the market.
Curative Biotechnology (CUBT) released its Q1 quarterly report for the period ending March 31, 2021. Key highlights include a significant increase in cash reserves from $160,607 to $564,546 and a reduction in debt from $528,893 to $75,373. The company successfully converted Series A and B Preferred shares to Common, strengthening its equity structure. The management team has expanded, adding seasoned professionals to direct its therapeutic development efforts, particularly in rare diseases including rabies and glioblastoma. Curative Biotech is set to file an IND with the FDA for a new retinal degeneration treatment by year-end.
Curative Biotechnology (OTC: CUBT) announced a trading symbol change from CTYX to CUBT and a corporate name change to better reflect its mission in rare disease therapeutics. Chairman Paul Michaels emphasized the transformation in mission and leadership with the addition of renowned scientists Dr. Kapil Bharti and Dr. Dimiter Dimitrov to the Scientific and Clinical Advisory Board. Bharti is noted for developing treatments for eye diseases, while Dimitrov focuses on antibody therapeutics. Curative plans to file an IND for a metformin reformulation to treat wet AMD.
Curative Biotechnology, Inc. (OTC: CUBT) announced a trading symbol change from CTYX to CUBT as part of its rebranding efforts. This name change reflects the company's mission to develop novel therapies for rare diseases. The company also appointed two experts to its Scientific and Clinical Advisory Board: Dr. Kapil Bharti and Dr. Dimiter Dimitrov, who will guide pre-clinical and clinical trials. Additionally, Curative plans to file an Investigational New Drug Application for a reformulated metformin treatment for wet Age-related Macular Degeneration by year-end.
Connectyx Technologies Holdings Group, Inc. (OTC: CTYX) announced its fiscal year 2020 results, highlighting a name change to Curative Biotechnology, Inc. and a symbol shift to CURB. The firm secured significant licensing agreements for innovative therapies, including CURB906 for brain tumors and IMT504 for rabies. They raised $1.09 million through financing and engaged auditors to become SEC reporting. The company aims for accelerated growth in 2021, supported by a strengthened management team in the biotech sector.
Connectyx Technologies Holdings Group (OTC: CTYX) announced the addition of three experienced professionals to its management team, including Richard Garr as CEO and General Counsel, Ron Bordens, Ph.D., as EVP of Technical Operations, and Michael Grace, Ph.D., as Chairman of the Scientific Advisory Board. The new team aims to accelerate drug development for novel therapies targeting rare diseases, including treatments for rabies and degenerative eye diseases. The company is also changing its name to Curative Biotechnology, Inc., effective Q1 2021.
Connectyx Technologies Holdings Group (OTC: CTYX) announced leadership changes with the addition of Richard Garr as CEO and General Counsel, Ron Bordens Ph.D. as Executive Vice President of Technical Operations, and Michael Grace Ph.D. as Chairman of the Scientific Advisory Board. These new appointments follow six months of advisory roles and aim to enhance the company's strategic initiatives, particularly in drug development for rare diseases. The company is accelerating programs targeting late-stage rabies and degenerative eye diseases, as well as pursuing innovative manufacturing solutions.
Connectyx Technologies Holdings Group (CTYX) has entered an Exclusive Patent License Agreement with the National Eye Institute (NEI) to utilize patented inventions for treating Retinal Degeneration (RD) with Metformin. The agreement covers U.S. provisional and international patent applications, allowing worldwide license rights. Metformin, an FDA-approved diabetes medication, will be reformulated for ophthalmic use targeting conditions like Stargardt disease, affecting children. The company aims to begin human testing by Q3 2022, marking a significant step towards addressing unmet medical needs in rare eye diseases.
Connectyx Technologies Holdings Group (OTC: CTYX) announced an Exclusive Patent License Agreement with the National Eye Institute to use Metformin for treating Retinal Degeneration. This agreement involves significant patent applications for developing Metformin into targeted therapies for degenerative eye diseases like Stargardt disease and AMD, affecting millions. The reformulated drug may follow a 505(b)(2) accelerated development path, with human testing anticipated by Q3 2022. Connectyx aims to enhance its portfolio of disease-modifying therapeutics.
Connectyx Technologies Holdings Group (OTC: CTYX) announced an Exclusive Evaluation and Commercialization Option License Agreement with the National Cancer Institute to utilize a novel monoclonal antibody for treating pediatric Glioblastoma. This orphan disease has a grim survival rate of under two years. CTYX aims for a First-in-Human clinical trial within 18 months, with plans for a combined Phase 1/Phase 3 trial to expedite development. The global patent rights cover treatments for both adult and pediatric Glioblastomas, vital in addressing a pressing medical need.
Connectyx Technologies Holdings Group (OTC: CTYX) has signed a definitive agreement with Mid-Atlantic BioTherapeutics to acquire worldwide rights for IMT504, an immunotherapy aimed at treating symptomatic rabies. IMT504 has received orphan drug designation in the US, providing tax credits and market exclusivity advantages. Rabies, with a near 100% fatality rate in late stages, has no treatment options currently. Connectyx aims to enter clinical trials by Q1 2022, with hopes for rapid FDA approval based on adaptive trial strategies.
